ES2619943T3 - Anticuerpos de alta afinidad que neutralizan la enterotoxina B estafilocócica - Google Patents

Anticuerpos de alta afinidad que neutralizan la enterotoxina B estafilocócica Download PDF

Info

Publication number
ES2619943T3
ES2619943T3 ES08712978.9T ES08712978T ES2619943T3 ES 2619943 T3 ES2619943 T3 ES 2619943T3 ES 08712978 T ES08712978 T ES 08712978T ES 2619943 T3 ES2619943 T3 ES 2619943T3
Authority
ES
Spain
Prior art keywords
amino acid
acid sequence
seq
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08712978.9T
Other languages
English (en)
Spanish (es)
Inventor
Philip M. Sass
Nicholas C. Nicolaides
Luigi Grasso
Marc Berger
Tao Sai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphotek Inc
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Application granted granted Critical
Publication of ES2619943T3 publication Critical patent/ES2619943T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES08712978.9T 2007-01-03 2008-01-03 Anticuerpos de alta afinidad que neutralizan la enterotoxina B estafilocócica Active ES2619943T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88327107P 2007-01-03 2007-01-03
US883271P 2007-01-03
US88840507P 2007-02-06 2007-02-06
US888405P 2007-02-06
PCT/US2008/000104 WO2008085878A2 (en) 2007-01-03 2008-01-03 High affinity antibodies that neutralize staphylcoccus enterotoxin b

Publications (1)

Publication Number Publication Date
ES2619943T3 true ES2619943T3 (es) 2017-06-27

Family

ID=39529113

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08712978.9T Active ES2619943T3 (es) 2007-01-03 2008-01-03 Anticuerpos de alta afinidad que neutralizan la enterotoxina B estafilocócica

Country Status (9)

Country Link
US (6) US8236932B2 (https=)
EP (2) EP2109622B1 (https=)
JP (3) JP5412293B2 (https=)
AU (1) AU2008205376B2 (https=)
CA (2) CA2924155C (https=)
DK (1) DK2109622T3 (https=)
ES (1) ES2619943T3 (https=)
PL (1) PL2109622T3 (https=)
WO (1) WO2008085878A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236932B2 (en) 2007-01-03 2012-08-07 Morphotek, Inc. High affinity antibodies that neutralize Staphylococcus enterotoxin B
US20110166076A1 (en) * 2008-09-10 2011-07-07 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
WO2013089877A2 (en) * 2011-09-27 2013-06-20 Albert Einstein College Of Medicine Of Yeshiva University Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs
CN103946236B (zh) * 2011-11-23 2018-02-16 弗·哈夫曼-拉罗切有限公司 表达cd40l的哺乳动物细胞及其用途
US20160039914A1 (en) * 2013-03-14 2016-02-11 Albert Einstein College Of Medicine Of Yeshiva University Humanized antibodies specific for staphylococcal enterotoxin b
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
US20230192896A1 (en) * 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
KR102124258B1 (ko) * 2018-10-19 2020-06-26 대한민국(관리부서 질병관리본부장) 신속 면역크로마토그래피법을 이용한 황색 포도알균 장독소 b 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주
EP4051711A4 (en) * 2019-11-01 2024-02-21 Magenta Therapeutics, Inc. ANTI-CD45 ANTIBODIES AND THEIR CONJUGATES
KR102274759B1 (ko) * 2020-01-16 2021-07-09 대한민국(질병관리청장) 황색포도알균 장독소 b에 특이적인 항체 및 이의 용도
CN119101153B (zh) * 2024-04-30 2025-07-08 中国人民解放军军事科学院军事医学研究院 一种葡萄球菌肠毒素b纳米抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2574089A (en) 1948-06-08 1951-11-06 Cochran Jacqueline Luggage case having a removable lining
US4854432A (en) 1988-07-06 1989-08-08 American Tourister, Inc. Suitcase having removable divider with clothing pockets
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
CA2194450A1 (en) 1994-07-06 1996-01-18 Truckin' Movers Corporation Convertible carrying case and work platform
US6036697A (en) 1998-07-09 2000-03-14 Scimed Life Systems, Inc. Balloon catheter with balloon inflation at distal end of balloon
CA2345023A1 (en) 1998-10-07 2000-04-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
US20050240009A1 (en) 2002-08-21 2005-10-27 Carr Francis J T-cell epitopes in staphylococcal enterotoxin b
WO2005023853A1 (ja) * 2003-09-05 2005-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute プロテアーゼ耐性ｓｅｂ改変体およびそれを含むワクチン
CA2596925C (en) 2005-02-08 2017-07-04 Km Biologics Co., Ltd. Method for improving expression level and stability of antibody
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
US8236932B2 (en) * 2007-01-03 2012-08-07 Morphotek, Inc. High affinity antibodies that neutralize Staphylococcus enterotoxin B

Also Published As

Publication number Publication date
CA2924155A1 (en) 2008-07-17
EP3138852A1 (en) 2017-03-08
PL2109622T3 (pl) 2017-06-30
WO2008085878A2 (en) 2008-07-17
AU2008205376A1 (en) 2008-07-17
CA2674382C (en) 2016-05-31
US20170121396A1 (en) 2017-05-04
JP5412293B2 (ja) 2014-02-12
EP2109622A2 (en) 2009-10-21
US9868780B2 (en) 2018-01-16
DK2109622T3 (en) 2017-02-13
US8236932B2 (en) 2012-08-07
US8895704B2 (en) 2014-11-25
AU2008205376B2 (en) 2012-07-12
US20150050276A1 (en) 2015-02-19
JP2013216673A (ja) 2013-10-24
US20180094048A1 (en) 2018-04-05
US8889846B2 (en) 2014-11-18
US20130183314A1 (en) 2013-07-18
WO2008085878A3 (en) 2009-02-26
CA2674382A1 (en) 2008-07-17
JP5881646B2 (ja) 2016-03-09
JP2016146824A (ja) 2016-08-18
US20120171223A1 (en) 2012-07-05
EP2109622B1 (en) 2016-11-09
US9359428B2 (en) 2016-06-07
JP6195946B2 (ja) 2017-09-13
US10364284B2 (en) 2019-07-30
JP2010514459A (ja) 2010-05-06
CA2924155C (en) 2020-02-11
US20140072553A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
ES2619943T3 (es) Anticuerpos de alta afinidad que neutralizan la enterotoxina B estafilocócica
Sawant et al. Toward drug-like multispecific antibodies by design
Van de Bovenkamp et al. Variable domain N-linked glycans acquired during antigen-specific immune responses can contribute to immunoglobulin G antibody stability
Xiang et al. Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies
Cassotta et al. A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients
US20220415436A1 (en) Computer assisted antibody re-epitoping
CA3116289A1 (en) Trem2 stabilizing antibodies
EP4442706A2 (en) Canine antibody libraries
CY1112876T1 (el) Πρωτεϊνες συνδεσης ειδικες για παρομοιους με ινσουλινη παραγοντες αναπτυξης και χρησεις αυτων
JP2020522261A5 (https=)
HRP20192218T1 (hr) Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene
BRPI0511782A (pt) anticorpos anti-cd3 e métodos de uso dos mesmos
BR112015004783B1 (pt) Anticorpo isolado totalmente humano, humanizado ou quimérico, que se liga especificamente a il-18, mas não se liga ao complexo il-18/proteína de ligação a il18, seu método de produção e seu uso, polinucleotídeo isolado, vetor de clonagem ou expressão, microrganismos transgênicos e seu método de produção, e composição farmacêutica e seu uso
BRPI0610796B8 (pt) anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
AR053514A1 (es) Anticuerpos dirigidos contra cd20 y sus usos
Kelly et al. Nonspecificity in a nonimmune human scFv repertoire
CN108475299B (zh) 从头抗体设计
Zielonka et al. The shark strikes twice: hypervariable loop 2 of shark IgNAR antibody variable domains and its potential to function as an autonomous paratope
Liu et al. The development of neutralizing antibodies against SARS-CoV-2 and their common features
JP2023106414A (ja) 真核宿主細胞において多量体タンパク質を産生する方法
Lee et al. A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions
Hollingsworth et al. Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants
Xiao et al. Deep sequencing and Circos analyses of antibody libraries reveal antigen-driven selection of Ig VH genes during HIV-1 infection
Rickert et al. Combining phage display with de novo protein sequencing for reverse engineering of monoclonal antibodies
Frese et al. An automated immunoassay for early specificity profiling of antibodies